REAL-WORLD EFFECTIVENESS OF ATEZOLIZUMAB PLUS BEVACIZUMAB IN THE PATIENTS WITH HEPATOCELLULAR CARCINOMA: A MULTIINSTITUTIONAL COHORT IN TAIWAN

被引：0
|
作者：
Kuo, Y. C. [1 ]
Chang, K. C. [2 ]
Chen, H. Y. [3 ]
机构：
[1] Linkou Chang Gung Mem Hosp, Taoyuan, Tao, Taiwan
[2] Chang Gung Mem Hosp, Taoyuan, Taiwan
[3] Linkou Chang Gung Mem Hosp, Dept Pharm, Taoyuan, Tao, Taiwan
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
RWD134
引用
收藏
页码：S475 / S475
页数：1
相关论文
共 50 条
  • [41] A real-world, multicenter study of atezolizumab plus bevacizumab in viral and non-viral advanced hepatocellular carcinoma patients from Asia and Europe
    Rossari, F.
    Tada, T.
    Shimose, S.
    Kudo, M.
    Yoo, C.
    Cheon, J.
    Finkelmeier, F.
    Lim, H. Y.
    Presa, J.
    Masi, G.
    Bergamo, F.
    Amadeo, E.
    Vitiello, F.
    Foti, S.
    Camera, S.
    Persano, M.
    Stefanini, B.
    Scartozzi, M.
    Rimini, M.
    Gardini, A. Casadei
    ANNALS OF ONCOLOGY, 2024, 35 : S82 - S82
  • [42] Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis
    Brown, Timothy J.
    Mamtani, Ronac
    Gimotty, Phyllis A.
    Karasic, Thomas B.
    Yang, Yu-Xiao
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (06) : 2345 - 2354
  • [43] Real-world experience of atezolizumab and bevacizumab for treatment of advanced hepatocellular carcinoma in a single tertiary center
    Raharjo, C. V.
    Joseph, R.
    Stratton, E.
    Levy, M.
    Prakoso, E.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 22 - 22
  • [44] The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey
    Akyildiz, Arif
    Guven, Deniz Can
    Ozluk, Ahmet Anil
    Ismayilov, Rashad
    Mutlu, Emel
    Unal, Olcun Umit
    Yildiz, Ibrahim
    Iriagac, Yakup
    Turhal, Serdar
    Akbas, Sinem
    Bayram, Ertugrul
    Telli, Tugba Akin
    Turkoz, Fatma Paksoy
    Ozcelik, Melike
    Erciyestepe, Mert
    Selvi, Oguzhan
    Gulbagci, Burcu
    Erturk, Ismail
    Isleyen, Zehra Sucuoglu
    Kahraman, Seda
    Akdag, Mutianur Ozkorkmaz
    Hamitoglu, Buket
    Unek, Ilkay Tugba
    Unal, Caglar
    Hacibekiroglu, Ilhan
    Arslan, Cagatay
    Azizy, Abdulmunir
    Helvaci, Kaan
    Demirci, Umut
    Dizdar, Omer
    Basaran, Mert
    Goker, Erdem
    Sendur, Mehmet Ali
    Yalcin, Suayib
    MEDICINE, 2023, 102 (45) : E35950
  • [45] Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study
    D'Alessio, Antonio
    Fulgenzi, Claudia Angela Maria
    Nishida, Naoshi
    Schoenlein, Martin
    von Felden, Johann
    Schulze, Kornelius
    Wege, Henning
    Gaillard, Vincent E.
    Saeed, Anwaar
    Wietharn, Brooke
    Hildebrand, Hannah
    Wu, Linda
    Ang, Celina
    Marron, Thomas U.
    Weinmann, Arndt
    Galle, Peter R.
    Bettinger, Dominik
    Bengsch, Bertram
    Vogel, Arndt
    Balcar, Lorenz
    Scheiner, Bernhard
    Lee, Pei-Chang
    Huang, Yi-Hsiang
    Amara, Suneetha
    Muzaffar, Mahvish
    Naqash, Abdul Rafeh
    Cammarota, Antonella
    Personeni, Nicola
    Pressiani, Tiziana
    Sharma, Rohini
    Pinter, Matthias
    Cortellini, Alessio
    Kudo, Masatoshi
    Rimassa, Lorenza
    Pinato, David J.
    HEPATOLOGY, 2022, 76 (04) : 1000 - 1012
  • [46] Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis
    Timothy J. Brown
    Ronac Mamtani
    Phyllis A. Gimotty
    Thomas B. Karasic
    Yu-Xiao Yang
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 2345 - 2354
  • [47] Real-world experience with atezolizumab plus bevacizumab (A plus /-B) in Hispanic patients with advanced hepatocellular carcinoma (HCC) at a Hispanic-majority cancer center.
    Parekh, Jay
    Newman, Neil
    Arellano, Luisa Marie
    Altermatt, Brittany
    Salazar, Mary
    Edwards, Shannon
    Balasubramanian, Lakshmi
    Denno, James
    Fuentes, Lorena
    Sun, LuZhe
    Arora, Sukeshi Patel
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 549 - 549
  • [48] EMERGING REAL-WORLD TREATMENT PATTERNS FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA (uHCC) PATIENTS FOLLOWING APPROVAL OF ATEZOLIZUMAB PLUS BEVACIZUMAB (A plus B) IN THE UNITED STATES (US)
    Singal, Amit G.
    Shamas, Natasha
    Secrest, Matthew H.
    Mahrus, Sami
    Tan, Amie
    Li, Daneng
    HEPATOLOGY, 2022, 76 : S1381 - S1382
  • [49] Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Galle, Peter R.
    Ducreux, Michel
    Kim, Tae-You
    Kudo, Masatoshi
    Breder, Valeriy
    Merle, Philippe
    Kaseb, Ahmed O.
    Li, Daneng
    Verret, Wendy
    Xu, Derek-Zhen
    Hernandez, Sairy
    Liu, Juan
    Huang, Chen
    Mulla, Sohail
    Wang, Yulei
    Lim, Ho Yeong
    Zhu, Andrew X.
    Cheng, Ann-Lii
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20): : 1894 - 1905
  • [50] THE EFFICACY AND SAFETY OF ATEZOLIZUMAB & BEVACIZUMAB IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA: THE REAL WORLD DATA
    Yoo, Sung Hwan
    Lee, Hyun Woong
    Lee, Jung Il
    HEPATOLOGY, 2023, 78 : S1898 - S1899
12345